Investigator |
Title |
Sponsor |
ID |
Dates |
Amount |
Charles T Quinn, MD |
A Pilot Study of Imatinib in patients with Sickle Cell Disease and Recurrent Vaso-occlusive Pain |
Purdue University |
PU - Quinn,Charles |
10/16/2019 - 10/15/2024 |
$83,071 |
Charles T Quinn, MD |
DISPLACE: Dissemination and Implementation of Stroke Prevention: Looking at the Care Environment |
University of Alabama-Birmingham (National Institutes of Health) |
000524452-002 |
01/01/2019 - 06/30/2019 |
$3,609 |
Cristina Tarango, MD |
ATHN 11 |
American Thrombosis & Hemostatis Network |
ATHN - Tarango,Crist |
09/01/2019 - 08/31/2020 |
$20,000 |
Cristina Tarango, MD |
Hemophilia and Thrombosis Center |
Hemophilia Foundation of Michigan |
Tarango, CHC,HFM |
06/01/2020 - 05/31/2021 |
$154,596 |
Cristina Tarango, MD |
Community Counts: Public Health Surveillance for Bleeding Disorders |
Hemophilia Foundation of Michigan (Ctr for Disease Control and Prevention) |
U27DD001155 |
09/30/2019 - 09/29/2020 |
$27,250 |
Cristina Tarango, MD |
Region V East Comprehensive Care Network for Bleeding Disorders |
Hemophilia Foundation of Michigan (Maternal & Child Health Bureau) |
H30MC24047 |
06/01/2019 - 05/31/2020 |
$22,000 |
Eric Mullins, MD |
Mechanisms linking hemostatic factors and neuroinflammatory disease |
National Institutes of Health (NIH) |
R01NS107258 |
03/01/2020 - 02/28/2021 |
$412,354 |
Joseph S Palumbo, MD |
Hemostatic Factors Drive Prostate Cancer Pathogenesis |
National Institutes of Health (NIH) |
R01CA193678 |
04/01/2020 - 03/31/2021 |
$356,850 |
Joseph S Palumbo, MD |
Coagulation factors as modifiers of the colon cancer microenvironment |
National Institutes of Health (NIH) |
R01CA204058 |
04/01/2020 - 03/31/2021 |
$356,850 |
Lisa M Littner LISW-S |
Health for Hemophilia |
The Hemophilia Alliance Foundation |
Littner, HAF |
04/01/2020 - 03/31/2021 |
$8,000 |
Lisa M Shook |
Sickle Treatment and Outcomes Research in the Midwest (STORM) |
Health Resources & Services Admin |
U1EMC27863 |
09/01/2019 - 08/31/2020 |
$536,250 |
Lisa M Shook |
Cincinnati Sickle Cell Project |
Ohio Department of Health |
03130011SK1320 |
07/01/2019 - 06/30/2020 |
$125,957 |
Lori Luchtman-Jones, MD |
Prospective validation of a venous thrombosis risk assessment model in critically ill children from the CHAT Registry (CHAT 1901) |
Children's Hospital Los Angeles |
1901 |
03/01/2020 - 02/28/2025 |
$8,033 |
Luke R Smart, MD |
Genetic modifiers of sickle cell anemia and hemoglobin F production in northwest Tanzania |
American Society of Hematology |
Smart, Luke:ASH |
07/01/2019 - 06/30/2020 |
$70,000 |
Luke R Smart, MD |
Bedside Expedited Testing for Anemia (BETA) |
Thrasher Research Fund |
Smart, Luke, TRF |
07/01/2019 - 06/30/2020 |
$8,335 |
Patrick McGann, MD-MS |
Maximizing Fetal Hemoglobin Responses to Hydroxyurea using Precision Medicine |
Doris Duke Charitable Foundation |
2017090 |
09/01/2019 - 08/31/2020 |
$330,000 |
Patrick McGann, MD-MS |
Therapeutic Response Evaluation and Adherence Trial: A Prospective Study of Hydroxyurea for Children with Sickle Cell Anemia |
National Institutes of Health (NIH) |
K23HL128885 |
06/01/2019 - 05/31/2021 |
$187,649 |
Russell Ware, MD-PHD |
A cloud-based decision support platform for precision dosing in sickle cell disease |
Cleveland Clin Lerner Col of Med of CWRU (National Institutes of Health) |
1232-Sub |
08/01/2019 - 07/31/2020 |
$119,250 |
Russell Ware, MD-PHD |
Validation of Cross-Species Biomarkers of DNA Damage |
Litron Laboratories (National Institutes of Health) |
R44ES028163 |
09/01/2019 - 08/31/2020 |
$39,147 |
Russell Ware, MD-PHD |
Realizing Effectiveness Across Continents with Hydroxyurea (REACH): A Phase I/II Pilot Study of Hydroxyurea for Children with Sickle Cell Anemia |
National Institutes of Health (NIH) |
U01HL133883 |
08/01/2019 - 07/31/2020 |
$676,152 |
Theodosia A Kalfa, MDPHD |
The Role of Erythroblastic Islands in Anemia of Inflammation |
National Institutes of Health (NIH) |
R01HL152099 |
04/01/2020 - 03/31/2021 |
$634,684 |
Current Year Direct |
$4,180,037 |